Abciximab for Prevention of Stroke Recurrence Before Endarterectomy in Symptomatic Carotid Stenosis
Status:
Terminated
Trial end date:
2005-05-01
Target enrollment:
Participant gender:
Summary
The purpose of the present prospective, randomized, double-blind, double dummy controlled
multicenter pilot study is to investigate whether abciximab, compared with aspirin, is able
to reduce the rate of recurrent ischemic strokes before and during carotid endarterectomy
[CEA] (primary endpoints); and the degree of carotid stenosis, number of microembolic signal
(MES) counts, number of ischemic infarcts at diffusion weighted imaging (DWI) and amount of
intraluminal thrombus at pathological examination (secondary endpoints) in patients with
ischemic stroke due to a >50% carotid stenosis who will undergo CEA.
Phase:
Phase 3
Details
Lead Sponsor:
University of Zurich
Collaborators:
Eli Lilly and Company Schweizerische Herzstiftung
Treatments:
Abciximab Antibodies, Monoclonal Immunoglobulin Fab Fragments